NetScientific ( (GB:EMVC) ) just unveiled an update.
PDS Biotechnology, a portfolio company of EMV Capital, has announced a registered direct offering of up to $22 million, with $11 million upfront and an additional $11 million contingent on warrant exercises. This offering involves new and existing healthcare-focused institutional investors and certain directors of PDSB. The proceeds will support research and development and general corporate purposes. This move is expected to bolster PDS Biotech’s financial position, aiding its clinical trials and potentially enhancing its market position in the immunotherapy sector.
More about NetScientific
EMV Capital plc, formerly known as NetScientific plc, is a deep tech and life sciences venture capital investment group with an international portfolio of high-growth companies. The company focuses on generating superior returns from fast-growing sectors and technologies, investing in early-stage IP-rich companies. EMV Capital holds direct equity stakes and carried interest in its portfolio companies, supporting growth through proactive management and Board representation. Headquartered in London, it is quoted on the AIM market of the London Stock Exchange.
YTD Price Performance: -2.26%
Average Trading Volume: 41,953
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £13.19M
For an in-depth examination of EMVC stock, go to TipRanks’ Stock Analysis page.